Major Shareholder at Novartis Calls for Board Change After Drug Trial Setbacks

One of Novartis' major shareholders has called for changes to the company's board of directors following setbacks in drug trials. The shareholder highlighted the current board's responsibility for these failures and argued that the board should be restructured. Negative results in drug trials have raised concerns about the company's research and development processes. The major shareholder emphasized the need for more effective oversight and strategic guidance on the board to prevent such setbacks from recurring. The call could put pressure on Novartis' future clinical trials and drug portfolio strategy. The shareholder's demand is interpreted as a sign of growing dissatisfaction with the company's management performance. No official statement has yet been made by Novartis management on the matter. It remains uncertain how the board will respond and how potential changes will affect the company's operational and financial performance. Not investment advice.